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Article highlights.  
 
• Mevalonate Kinase Deficiency (MKD) is a neglected disease with onset in infancy.  
• MKD clinical picture is characterized by recurrent fever attacks, abdominal pain arthralgia, 
lymphadenopathy and, in the most severe case, neurological involvement.  
• The main MKD pathogenic hypothesis is represented by a shortage of isoprenoid 
compounds that led to a defective geraylgeranylation of RhoA proteins and increased 
caspase-1-dependent inflammation.  
• Mitochondrial dysfunction and altered production of 25-hydroxycholesterol represent 
innovative pathogenic assumptions to understand the MKD progression.  
• The emerging evidences on MKD pathogenesis could widen the therapeutic approaches 
focused particularly on Mitochondrial-Target Antioxidants or squalene synthetase inhibitors.  
 
 
ABSTRACT 
  
Introduction: Mevalonate Kinase Deficiency (MKD) is a rare inborn disease caused by the 
mutation of mevalonate kinase gene. 
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The clinical phenotype encompasses recurrent fever episodes in combination with gastrointestinal, 
immunological, rheumatological and neurological complaints. No specific treatment is available, 
apart from the newly approved biologics (canakinumab), but MKD can be still considered an 
orphan-drug disease, since the identification of a reliable therapeutic target needs an improved 
knowledge on the pathogenesis of the disease, which is so far controversial. 
Areas covered: On one hand, shortage of isoprenoid compounds downstream of mevalonate led 
to a defective geranylgeranylation of RhoA/Rac proteins and increased caspase-1-dependent 
inflammation. On the other hand, recent studies pointed the attention to the pathogenic role of the 
mitochondrial dysfunction and to defective production of 25-hydroxycholesterol. These 
mechanisms are not exclusive of each other, as they can contribute to different pathogenic 
features of MKD.  
Expert opinion: Innovative therapeutic approaches to MKD may count upon various 
medicaments, such as isoprenoid compounds that can enter the metabolic pathway, specific 
enzyme inhibitors and mitochondria-targeted drugs. Some of these compounds have already 
passed the clinical phase for other uses and may be repositioned to the treatment of MKD, 
fostering the development of clinical trials.  
 
Keywords: rare disease  , cholesterol  , immunology  , inflammation   
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1.  INTRODUCTION 
  
Mevalonate kinase gene (MVK, 12q24.11, NM_000431) encodes for the mevalonate kinase (E.C. 
2.7.1.36), a peroxisomal enzyme of the cholesterol pathway. Mutations in this gene have been 
found causative of a rare orphan disease, called Mevalonate Kinase Deficiency (MKD, OMIM 
#260920) [1, 2].  
MKD belongs to autoinflammatory syndromes, a group of inborn errors of immunity presenting with 
recurrent, seemingly unprovoked, multi-organ inflammatory attacks. 
MKD includes different forms of disease severity ranging from the mildest 
Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS, MIM # 260920) to the more 
severe form called mevalonic aciduria (MA, OMIM #610377), depending on the extent of the 
enzyme defect [3-5]. 
To date, MVK mutations associated with MKD are 204 and are present in almost all the exons 
without a "hot spot" area. The replacement c.1129 G> A (V377I) (1129G> A) is present in the 
majority of HIDS patients, especially in Northern Europe (> 80%) which was shown founder effect 
made which would spread to the rest of Europe and USA. The V377I was found in homozygous in 
a few subjects, is usually in heterozygous combined with a second mutation associated with HIDS 
and / or MA phenotype [2,5].  
The clinical picture of MKD, as a whole, is characterized by recurrent inflammatory attacks with 
fever (4-5 days duration), arthralgia, rash, abdominal pain and diarrhea with early onset in infancy, 
subcutaneous edema and measles-like rash. Fever rises abruptly and often above 40°C, after 
which the temperature gradually returns to normal and, typically, recurrent febrile episodes 
diminish over the years. It can mimic other chronic disorders and thus many patients may remain 
undiagnosed for a long time and can be referred to a variety of subspecialty clinics, including 
neurology, gastroenterology, cardiology and genetics. Other clinical features have been associated 
with MKD in anecdotal reports or in small series, including retinitis pigmentosa, renal 
angiomyolipoma [6, 7] (Table 1). 
The complications of the disease, occasionally present in adults, include amyloidosis [8-10], 
adhesions in the abdomen and, very rarely, joint contractures [11]. 
Patients with MA display a worse phenotype with recurrent fever attacks, developmental delay, 
dysmorphic features, ataxia, cerebellar atrophy. The prognosis for MA is poor: more than 50% of 
patients die because of an inflammatory crisis in infancy, and very few survive to adolescence [12]. 
During flares, acute phase reactants (ESR, CRP, and white blood cell count) and inflammatory 
markers (interleukin (IL)-1β, IL-6, TNF-α) are increased in peripheral blood while high levels of 
mevalonic acid can be measured in urines [13]. In the periods between episodes, these exams 
tend to be normal, except in the most severe cases and in subjects with MA. In addition, anemia 
mild to moderate is usually present irrespective of the phase of disease and an increase in 
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transaminases and creatine phosphokinase is recorded in the most severe forms of the disease. 
MKD is typically associate with increased levels of IgD (and usually IgA), that is where the name of 
hyperglobulinemia D syndrome comes from. However, several reports highlighted that high IgD 
levels are not mandatory to MKD diagnosis [14, 15]. 
The distinction between MA and HIDS is based on the residual enzyme activity of MK, with levels 
below 1% of controls in subjects with MA, while a variable enzymatic activity, estimated between 1-
10%, is present in patients with HIDS. Measure of MK activity in fibroblast or in peripheral blood 
cells from patients is of particular importance when genetic analysis of MVK detects mutations 
without a known correlation with phenotype. This implies that the excretion of mevalonic acid in 
urine may differ significantly between the two phenotypes of the syndrome, ranging from 1-56 
mol/mol creatinine (in MA) at 0.004-0.028 mol/mol creatinine (in HIDS) [16]. Indeed, the measure 
of mevalonic acid in the urines collected during 24 hours of a febrile attack can serve as reliable 
and noninvasive diagnostic tool. Moreover, the detection of increased urinary mevalonate between 
febrile crises should be regarded as a score of greater severity of the disease. 
The diagnosis, indeed, must be confirmed by molecular analysis of the MVK gene to establish the 
mutations. 
 
2. MKD PATHOGENESIS 
  
The MKD pathogenesis is not yet completely known. The finding of pathogenic MVK mutations in a 
subject with the typical symptoms of MKD clearly confirm support the diagnosis of MKD. However, 
most of patients are in well health conditions outside the inflammatory crisis and it is not clear what 
mechanisms trigger the inflammation. The characteristic of seemingly unprovoked bouts of 
inflammation dominated by high production of the IL-1β allows classifying MKD among 
autoinflammatory disease. However, unlike other autoinflammatory diseases, MKD is not due to 
the mutation of genes directly involved in the control of innate inflammation. Indeed, the 
pathogenic mutations causative of most genetic autoinflammatory disorders involve genes 
codifying for components of the multiprotein platform called inflammasome. The most important 
and studied protein for autoinflammatory diseases is NOD-like receptor (NLR) pyrin domain-
containing 3 (P3), NLRP3 also indicated as NALP3 [17]. The NLRP3 is directly involved in 
activation of pro-caspase-1 to caspase-1, which in turn is required for processing the inflammatory 
cytokine, pro-IL-1β to the active form (IL-1β), a pyrogenic cytokine that appears to play a 
fundamental role in autoinflammatory disease with periodic fever, such as Cryopyrinopathies, 
Familial Mediterranean Fever, TNF Receptor Associated Periodic Fever and MKD itself [18, 19]. 
The production of IL-1β plays a crucial role in the pathogenesis as indicated by the dysregulated 
secretion of this inflammatory cytokine in peripheral blood cells of patients with MKD [20-22]. There 
is agreement that the increased production of this cytokine in MKD can be sustained both by 
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activation of the transcription factor NF-kB, which modulates the expression of inflammatory 
genes, and by the activation of caspase-1, which is responsible for the release of the active 
cytokine [23]. However, according to other evidences, a defect or delay in the phagocytosis of 
apoptotic leukocytes can also play a role, resulting in defective suppression of inflammation [24, 
25] (Figure 1).  
 
2.1 Mevalonate pathway in different districts of the body 
  
To unravel the pathogenesis of MKD and to identify the best targets for therapeutic intervention, it 
is fundamental to take into due consideration the different regulation of the cholesterol metabolism 
in the different district: systemic circle, liver, immune cells and central nervous system.  
Cholesterol is supplied to the organism both by diet (exogenous lipoprotein pathway), even if it 
accounts for a small percentage, and by endogenous biosynthesis, mostly occurring in the liver. 
Mainly the liver and macrophages are involved in regulating the balance of cholesterol in the 
organism and in tissues. To be roughly schematic, the liver produces large amounts of cholesterol 
to form bile acids and to load lipoproteins. The balance between uptake and synthesis of 
lipoproteins in liver is crucial to the maintenance of the body lipid homeostasis. Indeed, the excess 
cholesterol in tissues is mainly removed through High Density Lipoproteins, which are loaded with 
cholesterol. Alternatively, cholesterol is removed from tissues by macrophages engulfed with dead 
cell membranes [26]. 
While liver and macrophages play a major role in the metabolism of cholesterol for most tissues, 
brain cells have to count only on de novo synthesis, as the blood-brain barrier effectively prevents 
the passage of lipoproteins. Nonetheless, brain tissues, required in high quantities of cholesterol, 
as it is essential for the proper functioning of the central nervous system; neurons, in fact, need 
cholesterol to form the membranes of axons, dendrites, and synapses [27, 28]. Moreover, there 
are evidences that the homeostasis of this compound is not uniform in the different brain areas: the 
content [29] and the expression levels of cholesterol-specific enzymes show strong variations in 
the different regions of the brain [30, 31]. 
However, regulation of the mevalonate-cholesterol pathway in cell is not solely devoted to the 
production of cholesterol for cell membranes. Several intermediate products of this pathway have 
crucial roles in cell function and their regulation can vary hugely in different cells and tissues. This 
complexity makes it difficult to predict what effect a defective enzyme can have on the clinical 
phenotype. For this reason, appropriate animal and cellular models are necessary to understand 
the physiopathology of MKD and to study the pharmacologic intervention with compounds acting 
on this biochemical pathway.  
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2.2 Animal or cellular MKD models 
  
The possibility of using an instrument that reproduces as well as possible the inflammatory 
phenotype characteristic of MKD is crucial to identify molecular targets useful to develop future 
treatments for the disease. 
  
Genetic Model 
To date, an early issue in assessing the MKD pathogenesis is represented by the lack of a reliable 
genetic model. Knockout of MK in animals is not compatible with life, highlighting the importance of 
cholesterol and intermediate compounds for several vital cell functions. Unfortunately, in mice, the 
homozygous knock-in of mutations associated with human MKD was also unsuccessful. Thus, the 
only genetic mouse model of MKD has been obtained by the heterozygous deletion of one MVK 
allele; however, this model only partially reproduces the MKD-like inflammatory phenotype and 
does not show the features of neurological dysfunction [32]. 
Similarly, there have been difficulties in developing an in vitro genetic model. Recently a report 
showed that the knockdown of mevalonate kinase, using the silencing RNA (siRNA) technology, in 
a murine microglial cellular model (BV-2 cells) is not a suitable MKD model, because the NLRP3 
expression and the apoptosis does not correspond to the expression obtained from MKD patients 
[33]. 
  
Biochemical Model 
To overcome these limitations, in recent years, our and other groups have set an MKD model, both 
in vitro and in vivo, using pharmacological inhibitors to induce a biochemical imbalance mimicking 
the genetic deficiency of MK. Indeed, compounds such as statins or amino-bisphosphonates block 
the synthetic pathway of cholesterol and provoke an inflammatory dysregulation similar to that 
characteristic of MKD. On this substrate, the inflammatory attacks were triggered by the addition of 
a bacterial compound (lipopolysaccharide or muramyl-dipeptide) stimulating natural immunity 
activation. In this way, this model tried to reproduce the condition of patients with MKD, where the 
febrile attacks are often associated with minor external stimuli such as vaccination, infection or 
physical exertion [34]. 
The results obtained from both monocytes and neuronal cell lines treated with such inhibitors show 
that the shortage of intermediate compounds downstream of mevalonate can induce an 
inflammatory phenotype. Using the same experimental approach, mice with impaired biosynthesis 
of mevalonate-derived isoprenoid, displayed an increased inflammatory reactivity to the 
inflammatory stimulus muramyl-dipeptide [35]. This model appears to be particularly consistent 
with MKD, since it reproduces the molecular markers typical of the disease in humans (SAA Serum 
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amyloid A, inflammasome activation, biosynthesis of inflammatory cytokines), regardless of the 
mouse strain used [36]. 
The availability of these models, even with their weaknesses and limitations arising from a 
biochemical system, offers a valuable opportunity to address the study of the pathogenesis of 
MKD. 
This is particularly important to investigate the neurological features in MA [37, 38]. In fact, whilst 
peripheral blood cells obtained from patients can allow studies relevant to systemic inflammation, 
no neurological tissues can obviously be available for ex vivo researches.  
Moreover, the establishment of accurate in vitro and in vivo models for MA can represent a first 
step towards a better understanding the neuroinflammatory events occurring not only in MA, but 
also in other neurodegenerative disorders in which the cholesterol pathway is involved, including 
Alzheimer's disease, Huntington's disease, Parkinson's disease, Niemann-Pick type C disease and 
Smith-Lemli Opitz syndrome [39].  
 
2.3 Shortage of isoprenoids underlies MKD inflammation 
 
The defects in MK, logically could suggest that an accumulation of upstream intermediates, like 
mevalonate, occurs in MKD and related diseases and that this accumulation could be responsible 
for the pathological features of the diseases. On the contrary, the experiences with statins and the 
evidences that these drugs can block the pathway without resulting in inflammatory processes, 
suggest that the pathogenesis arises likely from a shortage of downstream products, rather than 
the accumulation of upstream intermediates [40]. 
Indeed, it was shown that the decrease of the intermediate isoprenoid levels, is responsible for the 
increased secretion of inflammatory cytokine IL-1β in MKD [21]. However, literature data 
demonstrated that even though MK enzyme activity is reduced and the residual MK levels are 
below detection levels in cultured skin fibroblasts from MA patients, the de novo biosynthesis of 
cholesterol and non-sterol isoprenoids can be sufficient [40, 41]. This paradox is probably due to 
the compensatory induction of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
leading to increased concentration of mevalonate. Indeed, the increased substrate of MK may 
allow the production of sufficient amount of the product [41, 42]. However, albeit sufficient in most 
physiological condition, this mechanism may be overcome in stress conditions, when the organism 
may needs higher synthesis of mevalonate-derived isoprenoids and cholesterol. Several studies 
highlight that the inflammatory phenotype associated with MKD is attributable to the inability of this 
system to compensate an instant further decrease in the MK residual activity or an increased 
usage of some isoprenoid compound. For example, it was suggested that the regulation of the 
immune response may require and extra-use of isoprenoid intermediates [18, 43].  
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2.4 Crucial role of defective geranylgeranylation of Rho and Rac in inflammation 
 
The complex mechanism activated by mevalonate block and supported by NLRP3 implies a 
shortage of isoprenoids and in particular non-sterols isoprenoids, such as geranylgeranyl-PP 
(GGPP). Isoprenylation with GGPP modulates the function of some membrane-bound proteins 
involved in the control of inflammatory response, proliferation, and apoptosis, such as the small 
GTPases of the Ras homolog gene family (RhoA) [44, 45]. Thus, depletion of GGPP can lead to 
impaired prenylation of such GTPases, resulting in an unbalanced control of inflammation. 
Furthermore, isoprenoids and sterols derived from mevalonate can also play a direct role in DNA 
transcription, enzymatic regulation and response to oxidative stress [46-48].  
Notably, environmental factors can act on this scenario in different ways: nutritional factors can 
influence the availability of substrates and the regulation of various enzymes; immune stimuli such 
as infections and vaccinations can trigger an inflammatory response that involves several 
prenylated proteins [49]; oxidative stress of various natures can exceed the antioxidant capacity of 
a defective mevalonate pathway [50, 51]. 
  
2.5 Mitochondrial dysfunction in the pathogenesis of inflammation 
 
Recent evidences of the literature point out that to understand the pathogenesis of MKD is 
necessary to focus on the role of the mevalonate pathway on the modulation of autophagy. 
Autophagy can be triggered by mitochondrial dysfunctions, when the energy produced is reduced 
and the cell activates a saving mode to preserve its integrity. This program can lead to reduced 
performances of the cells, metabolism, and reuse of macromolecules and digestion of damaged 
mitochondria.   
Recent literature evidence emphasizes that mitochondrial damage and induction of apoptosis can 
be due to various intracellular stress conditions, including DNA damage, cytotoxic insult, oxidative 
stress, infections. These various stimuli act by inhibiting or activating a particular anti- and pro-
apoptotic Bcl-2 family member [52]. The Bcl-2-associated X protein (Bax) is known to be a very 
important pro-apoptotic protein promoting the formation of channels into the mitochondria. The 
Bax-induced channels formed in the mitochondria are important for the dissipation of the 
mitochondrial transmembrane potential (Δψm), the inhibition of the respiratory chain and the 
interruption of the production of reactive oxygen species (ROS) [53]. Similar mitochondrial 
dysfunctions also represent a central causal factor in the pathogenesis of neurodegenerative 
diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and many others 
[54]. 
Recent studies on the action of genistein, an isoflavonoid compound acting on the mevalonate 
pathway, established a link between this pathway and oxidative stress in neurons. In particular, 
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genistein is able to recover the ROS production, to favor an anti-apoptotic Bcl-2/Bax ratio and 
contrast the NF-kB and MAPK inflammatory pathways. The potential neuroprotective and 
antinflammatory action of this natural compound may indirectly support the role of mitochondrial 
stress in MA [55]. 
  
2.6 Defective 25-hydroxycholesterol may underlie hyperimmunoglobulinemia D and 
inflammation 
  
About 10 years ago, a pioneering work of Goldstein [56] described the hydrophobic molecule 25-
hydroxycholesterol (25-HC) within the metabolic pathway of cholesterol. Since then, many studies 
have followed with the aim of establishing a biological role for this molecule [57-59]. In particular, 
25-HC is a lipid with immunoregulatory potential, produced by macrophages to downregulate the 
adaptive immune response [60]. Of note, the lack of 25-HC can be responsible for an increased 
production of Immunoglobulin A, which is typical of the most severe forms of MKD (such as MA) 
(Table 1). Furthermore, other studies showed that 25-HC could suppress the activation of NLRP3 
and consequently the production of inflammatory cytokines such as IL-1β [60]. Based on this data, 
it could be logical to hypothesize that a shortage of 25-HC may play a role in the pathogenesis of 
inflammation and hyperimmunoglobulinemia in MKD [61]. However, recent data showed that 25-
HC could have as well inflammatory effects, as in the case of cerebral inflammation associated 
with X-linked adrenoleukodystrophy [62]. Thus, the role of 25-HC in MKD remains controversial. 
 
3. DRUGS ACTING ON THE MEVALONATE PATHWAY AND POTENTIAL ROLE IN MKD 
 
Drugs acting on the mevalonate pathway may have variable effects on inflammation, with 
sometimes-unpredictable consequences in relation to dosage. In fact, the enzymes in the 
mevalonate pathway are highly regulated according to the availability of substrates and products. 
Such drugs have the ability to interfere with the metabolic pathway and are described in the 
following paragraphs (3.1 to 3.5), while in Chapter 4 actual and future therapeutic options for MKD 
will be discussed.  
  
3.1 Statins 
  
Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering drugs, acting 
on the rate-limiting step in the cholesterol pathway. The statins, indeed, act upstream of the 
mevalonate pathway by reducing the availability of mevalonate and the production of endogenous 
cholesterol [63-66]. 
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Statins have been considered to treat MKD, with the aim of inducing a compensatory effect on the 
residual mevalonate kinase activity. In a small group of HIDS patients, continuous treatment with 
simvastatin seemed associated with a lowered number of inflammatory crisis [67]. Nevertheless, 
the treatment with lovastatin in patients with MA led to a severe worsening of the clinical symptoms 
[68]. Taken together, these data suggest that statins can allow some improvement in subjects with 
milder diseases, like HIDS phenotype, while they will worsen the defect in subjects with more 
severe deficiency, such as MA. Thus, the use of statins in MKD remains controversial. Of note, 
several studies showed that statins could exert either anti- or pro-inflammatory effects in slightly 
different conditions [69]. 
 
3.2 Amino-bisphosphonates 
  
The amino-bisphosphonates are nitrogenous bisphosphonates with a strong effect in preventing 
bone resorption. Thanks to their chemical structure with two phosphate groups, these drugs are 
highly concentrated in bones where they act by inhibiting the function of osteoclasts. The high 
concentration of the drug reached in bones makes the amino-bisphosphonates particularly useful 
to prevent and treat osteoporosis, but also to contrast bone inflammation or bone metastasis. In 
particular, the amino-bisphosphonates such as alendronate, pamidronate, zoledronate, act on 
farnesyl diphosphate synthase (FPPS), just downstream of mevalonate kinase and or on other 
enzymes in the pathway to cholesterol, reducing in a variable manner the availability of isoprenoid 
intermediates. Inhibition of mevalonate pathway enzymes leads to various biological effects, 
including inhibition of osteoclast or tumor metastatic cells [70-72]. Alike occurs in MKD, the action 
of the amino-bisphosphonates leads to an accumulation of mevalonate and at the same time the 
reduction of downstream compounds of FPPS. 
Amino-bisphosphonates can be either anti- or pro-inflammatory, depending on the experimental 
context, similarly to what occurs for statins [73, 74]. The different effects may be related to their 
different ability to be metabolized by the cells [75]. 
 
3.3 Plant-derived isoprenoids 
 
Isoprene (also called isoprene units) is the common name for 2-methyl-1,3-butadiene, a compound 
that contains five carbon atoms, characterized by a branched "head" and a "tail". These ends of 
each isoprene unit can be joined “head-to-head”, “head-to-tail” or “tail-to-tail” to form different 
terpenes. Terpenes are a class of lipids: they can be hydrocarbons or alcohols containing oxygen, 
aldehydes or ketones. 
To date, there are more than 20,000 known terpenes. Many plants, particularly conifers, produce a 
huge variety of them and some insects. Terpenes are the main components of resins and essential 
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oils of plants, mixtures of substances that give each flower or plant a distinctive odor or flavor. 
They, also, are the biosynthetic precursors of steroids and cholesterol. Many flavorings used in 
foods and fragrances were derived from natural terpenes or terpenoids, as well as many perfumes 
and flavors found in plants and known as essential oils. 
Plant Moreover, isoprenoids are can be found as intermediate compounds of the mevalonate 
pathway, so that while some of the plant isoprenoids can enter the metabolic pathway in humans 
(i.e. geraniol, farnesol, geranylgeraniol, etc.), or can act as enzyme inhibitors (i.e. menthol, 
limonene, etc).   
The geraniol (GOH) for example, is a terpene alcohol extracted from certain types of plant 
(geranium, orange, vervain, myrtle, lemon balm) and commonly used in perfumery and food 
industry. The geraniol, relatively abundant in nature, is readily soluble in alcohol and in ether, with 
excellent good chemical stability and fat solubility, appearance that makes it ideal for a good 
absorption through different routes of administration. Some authors have already described the 
use of geraniol for topical use [76] or as an adjunct to anti-cancer drugs [77]. Likewise, menthol 
(MOH) is also a monoterpene, the active ingredient in the essential oil content of mint. Strongly 
aromatic and bitter, menthol is particularly known for its antiseptic, antispasmodic and local 
anesthetic action. The inhalation of the vapors that developed by placing a few drops of alcoholic 
solution of menthol in boiling water is famous for its ability to relieve the bronchial disorders and 
nasal congestion; menthol in fact can act as expectorant and disinfectant. Taken orally, the 
menthol is also used as anti-fermentative, antiseptic (facilitates the excretion of bile and runoff), 
refreshing and spasmolytic (reduces intestinal motility), which is useful in the presence of colics of 
the upper gastrointestinal tract, biliary tract and colon irritations, such as irritable bowel syndrome 
[78, 79]. 
It What is also very interesting from the medical aspect is the antinflammatory properties 
highlighted in studies on geranylgeraniol (GGOH), a diterpene soluble in organic solvents such as 
alcohol and acetone. 
Moreover, some of these compounds are already used as adjuvants in cancer therapies and as 
anti-metastatic agents [77, 80]. 
  
3.4 Inhibitors of prenylation 
  
Prenylation inhibitors act individually on the enzymes farnesyltransferase (FT) and 
geranylgeranyltransferase (GGT), which catalyze the transfer of isoprenoid "activated" groups 
(FPP or GGPP) on polypeptide chains. 
The characterization and the role of farnesylation and geranylgeranylation protein have been made 
possible by using specific inhibitors: inhibitors of farnesyltransferase (FTI) and 
geranylgeranyltransferase (GGTI). 
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The FTI act on different mechanisms of inhibition: some of them, such as manumycin A (ManA), a 
natural compound derived from Streptomyces, belong to the class of isoprenoid derivatives, in this 
case of the FPP analogs, while others, to the class of peptidomimetic. 
The inhibitors of GGT act similarly to FTI as competitors. The discovery that some 
geranylgeranylated proteins are involved in pathological processes such as cancer, inflammation, 
and viral infections, has led to a growing interest in the study of GGT as a possible therapeutic 
targets. They have been described several peptidomimetic GGTI, such as GGTI-298 and GGTI-
2154, both amino benzoic acid derivatives [81]. Recently it has been observed that some inhibitors 
belonging to the class of FTI can also inhibit GGT-type 2, also known as Rab-GGT since it is 
specific for Rab proteins [82]. 
The RAS family of proteins must be prenylated to properly perform their function and therefore are 
the main targets of such inhibitors. In particular, the FTI can inhibit RAS, while the GGTI-type 1 
inhibit Rho and Rac [82, 83]. 
  
3.5 Zaragozic acid 
  
Noteworthy is the effect of the zaragozic acid (ZAA), an inhibitor of squalene synthase. ZAA can 
reduce the synthesis of cholesterol, redirecting the flux throughout the cholesterol pathway to 
isoprenoids biosynthesis and functioning as a potential new cholesterol lowering agent [83-85]. 
ZAA is an inhibition of the competitive type, because it mimics the enzyme substrate presqualene-
PP, which typically forms during the reaction leading to the synthesis of squalene [86]. 
Recently ZAA has been proven to inhibit the hyper-inflammatory response in cellular models of 
MKD, by diverting mevalonate intermediates toward geranylgeranylation rather than to the 
synthesis of squalene. 
  
4. PHARMACOLOGIC OPTIONS IN MKD 
  
Although in recent years treatments for these rare diseases have been developed, it is worthy 
highlighting that, to date, there is no pathway-oriented treatment available for MKD. Indeed, current 
options are primarily intended to prevent or alleviate inflammatory symptoms, while future 
pharmacological treatments have the goal to be more close to the pathogenesis of the disease and 
more effective for patients with severe MKD (Figure 2). 
  
4.1 Current MKD treatments and biological drugs 
  
Several drugs have been used in MKD, but few of them still maintain a role in the treatment of the 
disease. In particular, the disease usually shows a good response to corticosteroids, but the 
adverse effects of these drugs can soon overcome the benefits, in particular when there is a need 
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for prolonged treatment. The major side effects associated with the traditional MKD treatments are 
a headache, stomach ulcers and kidney damage [4]. 
While antinflammatory drugs and steroids on demand provide acceptable control of symptoms in 
patients with milder forms of the disease, lifelong treatment with biological drugs (such as Anakinra 
or Canakinumab) [87, 88] is usually required for patients with high recurrence of severe 
inflammatory attacks. The response to anti-IL-1 biologics confirms once more the autoinflammatory 
nature of MKD. 
Anakinra is a recombinant, non-glycosylated, IL-1Ra, an endogenous antagonist that binds to IL-1 
receptors and inhibits the inflammatory effects of IL-1: it is administered subcutaneously and 
present a high bioavailability (95%). Other anti-IL-1 biologics include Rilonacept, a fully human 
fusion protein that incorporates the extracellular domains of the IL-1 receptor linked to the Fc 
portion of IgG1 and Canakinumab, a monoclonal antibody specific for IL-1β. Canakinumab, 
approved both in Europe and USA, has been studied for the treatment of rheumatologic diseases 
such as rheumatoid arthritis and systemic juvenile idiopathic arthritis, and for autoinflammatory 
diseases such as cryopyrin-associated periodic syndrome (CAPS). Very recently, Canakinumab 
has been approved by US Food and Drug Administration (September 2016) and by European 
Medicines Agency (December 2016) as treatment for MKD after the substantial results obtained in 
a Phase III Study (www.clinicaltrials.gov, NCT02059291). 
These biologicals have been shown effective in controlling MKD-related inflammation in clinical 
reports. However, the use of Anakinra is hindered by the need of daily painful injections, even if 
some patients well tolerate this treatment and then get good improvements [65, 66]. Canakinumab 
seem to be more effective, but it is not always able to completely control the disease, in particular 
in cases with severe disease. Moreover, biologics, especially Canakinumab, are very expensive 
and, at today, the dosing is still a matter of investigation. To date, the only valuable therapeutic 
option for patients with MA is hematopoietic stem cell transplantation, which however is burdened 
with a series of risks and complications [89, 90].  
  
4.2 Future directions  
  
The aim of the innovative pharmacological strategies is to obtain a more complete control of the 
disease than what can be achieved with cytokine inhibitors. An ideal causal therapy is expected to 
control all the different signs of the disease, including the neurologic and the lymphoproliferative 
signs, which are not completely targeted by current treatments. Furthermore, anti-cytokine 
biologicals have just a theoretical risk of infections: on a particular ground it is recommended to 
pay attention to the risk of the infection in patients treated with anti-IL1, and this may make difficult 
to discriminate if the inflammatory events during the therapy are due to this is flare of infections.  
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The easier therapeutic approach would be to exploit the supplementation with plant isoprenoids 
that can enter the mevalonate pathway compensating for the shortage of endogenous isoprenoids. 
This approach is based on the experimental evidence of the role of the shortage of isoprenoids in 
MKD inflammation. Moreover, several plant isoprenoids have been reported to have 
antinflammatory properties and could represent an attractive therapeutic opportunity thanks to their 
commercial availability, low cost, oral bioavailability and low toxicity. Moreover, recent literature 
data have showed that these natural products can also regulate in central nervous system, in 
particular, controlling motor and cognitive function [91]. 
Nevertheless, a limit to the translational of plant isoprenoids to the therapeutics of MKD can be 
represented by the amount of substance needed to have the antinflammatory benefit in vivo, which 
could be above the tolerated doses.  
Another approach is based on the use of inhibitor enzymes that can diverge the flux of isoprenoids 
toward antinflammatory molecules. This is the case for FTIs, like the such as Tipifarnib (R115777, 
Zarnestra™) and Lonafarnib (SCH66336, Sarasar™), which showed their potential use as 
antiparasitic, antifungal, antiviral and anticancer like, thanks to their effects exerted on 
oncoproteins such as RAS [92]. Preliminary in vitro studies on MKD monocytes treated with 
Tipifarnib and geraniol showed a significative reduction of IL-1β production, supporting the idea 
that an effective therapy for MKD may need combinatory approaches. 
Another attractive therapeutic possibility is represented by Lapaquistat (TAK-475, Takeda) [93, 94], 
an analogue inhibitor of zaragozic acid, a squalene synthetase inhibitor, which is a drug that 
underwent extensive clinical trials as cholesterol lowering agent 10 years ago with a good safety 
profile [95-98]. The possibile advantages for this compound are that it has already passed all the 
clinical stages and that could be evaluated in clinical trials and it can be administerly orally. 
 
The potential use of Lapaquistat seem to be in contrast with data showing a role for defective 25-
HC in MKD, as squalene synthase inhibition is expected to lower even more the levels of 25-HC 
[34]. However, the role of 25-HC remains controversial, as in adrenoleukodystrophy this molecule 
seem to be responsible for activation of NLRP3 and neuroinflammation [62]. Due to the complex 
regulation of the mevalonate pathway, only pre-clinical studies in animals and pilot studies in 
human will clarify this controversy indicating the correct direction for innovative treatments of MKD.  
Drugs belonging to the Mitochondrial-Target Anti-oxidants (MTAs) family, such as MitoQ, 
Mitotempo, represent as well a promising pharmacological approach and MitoVitE could potentially 
be effective in tackling the disease. MTAs, which are well known and well characterized for their 
anti-oxidant and mitochondrial protective activity in response to Bax, could indeed be potential 
candidate molecules to improve MA treatment. Moreover, MTAs are mitochondria-targeted drugs, 
several hundred folds more potent at in preventing mitochondrial oxidative damage than an 
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untargeted antioxidant [99] and, once accumulated into mitochondria, MTAs are able to inhibit step 
by step the activation of programmed cell death pathways [100]. 
 
5. EXPERT OPINION  
  
MKD is still a rare orphan drug disease with onset in infancy. Only drugs able to reduce the 
inflammatory symptoms are used in clinical practice, often with incomplete control of symptoms. 
Thus, patients with severe MKD still tend to have a poor quality of life. 
Patients with mevalonic aciduria, indeed, have high morbidity and reduced life expectancy in spite 
of current treatments. In some cases, while attenuating the flares, the treatments (especially with 
glucocorticoids) can lead to a chronic course of disease with weaker but constant symptoms.  
Furthermore, recent data indicate that MKD often remains misdiagnosed for years and the burden 
of MKD may be even greater than expected. Thus, the development of an effective drug to cure 
classical MKD might provide novel options for a larger number of patients than those suffering from 
diagnosed MKD.  
Moreover, the development of new models, both in vitro and in vivo, that can reproduce the 
neurological involvement in MA, is crucial to improve the knowledge on its pathogenesis, which is 
still unknown, and to develop new therapies able to improve the pathological conditions of patients. 
The dietary approaches have not yet considered. Even if MKD may be associated with low 
cholesterol, reducing the intake of cholesterol with diet may have a beneficial effect in MKD, by 
inducing an upregulation of the endogenous biosynthetic machinery.  
In general, it is important to emphasize that MKD belongs to the family of the autoinflammatory 
syndromes (AIS), a group of rare disorders, often underestimated or misdiagnosed and 
characterized by difficult therapeutic issues. 
From a scientific point of view, the AIS provide a clear model to understand the mechanisms 
involved in controlling inflammation and to study how combined mutations in functionally related 
genes may condition these pathologies as well as more common inflammatory disorders. 
Furthermore, in-depth knowledge on autoinflammatory disease may allow identifying novel targets 
for antinflammatory therapies, both for AIS and AIS-like disorders. In particular, studying the 
potential impact of manipulation of the mevalonate pathway on inflammation may open novel 
avenues for antinflammatory therapies. The identification, also, of epigenetic signatures associated 
with the development of AIS in genetically predisposed individuals may provide new tools to trace 
how environment and medical treatments influence the course of the disease. 
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TABLES LEGENDS 
 
Table 1. Mevalonate kinase deficiency clinical phenotype based on the typical signs and 
symptoms observed in the patients. 
 
FIGURES LEGENDS 
 
Figure 1. 
Pathogenesis of inflammatory processes in Mevalonate Kinase Deficiency (MKD). BisP: 
bisphosphonates; CH25H: cholesterol 25-hydroxylase; FTI: farnesyltransferase inhibitors; GGTI: 
geranylgeranyl transferase inhibitors; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; MK: 
mevalonate kinase; S Synth: squalene synthase; ZAA: zaragozig acid. 
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Figure 2. 
Therapeutic options in Mevalonate Kinase Deficiency. 
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 Typical 
Others 
(may be associated with most 
severe disease) 
Clinical symptoms 
Recurrent episodes of fever 
Arthralgia/arthritis  
Abdominal pain 
Diarrhea 
Lymphadenopathy 
Enlarged spleen  
Hepatopathy 
Retinitis pigmentosa 
Renal angiomyolipoma 
Cataract 
Nephritis 
Diabetes insipidus 
CNS involvement 
Amyloidosis 
Laboratory features 
Increased neutrophils, 
Raised CRP, 
Anemia, 
Increased urinary mevalonic 
acid, 
High IgD levels 
Increased immunoglobulins of 
various classes (IgA, IgM) 
In some cases, 
hypogammaglobulinemia 
 
 
Table 1. Mevalonate kinase deficiency clinical phenotypes based on the typical signs and symptoms 
observed in the patients. 
 
